Lupin gains on launching Meloxicam Capsules

28 Dec 2020 Evaluate

Lupin is currently trading at Rs. 982.50, up by 6.35 points or 0.65% from its previous closing of Rs. 976.15 on the BSE.

The scrip opened at Rs. 988.55 and has touched a high and low of Rs. 989.00 and Rs. 975.25 respectively. So far 106763 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1121.85 on 18-Sep-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 991.80 and Rs. 875.00 respectively. The current market cap of the company is Rs. 44618.93 crore.

The promoters holding in the company stood at 46.91%, while Institutions and Non-Institutions held 40.21% and 12.60% respectively.

Lupin has launched Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration (USFDA). Meloxicam Capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc., and indicated for management of osteoarthritis (OA) pain.

Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately $11 million in the U.S. (IQVIA MAT October 2020).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. 

Lupin Share Price

1635.00 -52.75 (-3.13%)
14-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1545.25
Dr. Reddys Lab 5861.00
Cipla 1356.95
Zydus Lifesciences 984.75
Lupin 1635.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.